Open access peer-reviewed chapter - ONLINE FIRST

Kidney Injuries in Sickle Cell Disease

Written By

Samit Ghosh

Submitted: January 10th, 2022 Reviewed: January 24th, 2022 Published: February 23rd, 2022

DOI: 10.5772/intechopen.102839

IntechOpen
Sickle Cell Disease Edited by Osaro Erhabor

From the Edited Volume

Sickle Cell Disease [Working Title]

Dr. Osaro Erhabor

Chapter metrics overview

48 Chapter Downloads

View Full Metrics

Abstract

Sickle cell disease (SCD), characterized by the presence of unstable sickle hemoglobin in the homozygous state (HbSS), results in progressive organ damage and early mortality with the median age of death in the 40s. The kidney is one of the most severely affected organs in SCD. Kidney diseases gradually develop in individuals with SCD. Microalbuminuria is evident in childhood, progressing to apparent proteinuria, deteriorating glomerular filtration rate (GFR) in early adulthood. While CKD becomes prevalent in adults. Moreover, among SCD patients, exacerbation of anemia is an independent risk factor for acute kidney injury (AKI) which is a predisposing factor for CKD and End Stage Renal Diseases (ESRD), altogether contributing to 16–18% mortality among this patients’ population. The pathogenesis of renal diseases in SCD is not completely understood. While epidemiological studies have shown a strong association between rate of hemolysis, severity of anemia and CKD, intrinsic inflammatory, oxidative and hypercoagulative stress that contribute to the characteristic endothelial dysfunction also promotes development of renal diseases in SCD. This chapter will elaborately discuss current research on the pathogenesis of AKI, AKI-to-CKD transition and future research perspectives for development of novel therapeutic strategies.

Keywords

  • sickle cell disease
  • hemolysis
  • endothelium
  • AKI
  • CKD

1. Introduction

Kidney diseases are a major clinical concern in sickle cell disorders (SCD). Acute kidney injury (AKI) as well as chronic kidney disease (CKD) is associated with higher risk of inpatient mortality, prolonged hospital stay and expensive hospitalizations [1, 2]. While an estimated 100,000 people are affected by SCD in the United States (US) [3, 4, 5], about 20–25 million people are living with SCD worldwide and the number is expected to increase by about 30% globally by 2050 [6]. In the US, the majority of healthcare for SCD is attributed to in-patient hospitalization for acute complications with an estimated annual cost of $953,640 per patient per year [7]. Progressive kidney disease leads to significant morbidity and mortality in both pediatric and adult patients with SCD. Sickle cell nephropathy (SCN) comprehends a spectrum of renal abnormalities that begins in childhood and may progress to advanced renal disorders in adulthood. In contrast to mild renal manifestations of sickle cell nephropathy includes decreased urinary concentrating ability, impaired renal acidification and potassium secretion, hematuria and proteinuria, progressive kidney disease leads to significant morbidity and mortality in both pediatric and adult patients with SCD. Acute Kidney Injury (AKI) causes sudden drop in kidney function and promotes chronic kidney disease (CKD) and end stage renal disease (ESRD) [8, 9, 10]. In SCD, incidences of AKI are common among hospitalized SCD patients [11, 12, 13] and it is associated with increased mortality in those admitted to intensive care unit [14]. It is also an independent risk factor for increase morbidity, longer hospitalizations, and increased costs [15] as well as with risk for CKD progression in SCD [16]. Approximately 30% of SCD individuals develop CKD by adulthood and a large proportion of this sub-population develops ESRD [17]. The annual rate of incidence of AKI and reported CKD is 2–3-fold higher among SCD patients compared to non-sickle individuals [2]. Although newborn screening along with early intervention decreased early childhood mortality in SCD, accumulation of kidney diseases and age dependent renal deterioration of renal health poses increased risk of mortality in this population.

Advertisement

2. SCD pathophysiology and susceptibility to acute kidney injury

The genetic basis of SCD includes a single point mutation in the beta-globin chain of hemoglobin resulting in a morphologically and functionally different red blood cells (RBC). The modified hemoglobin (HbS) polymerizes under hypoxic condition causing RBC sickling [18, 19]. This characteristic feature of SCD leads to two major pathophysiological consequences, namely, vasoocclusion and hemolysis [20]. Moreover renal medullary hypoxia, acidosis, hyperosmolarity and reduced blood flow contribute to elevated endothelial adhesion and recurrent ischemia–reperfusion (IR) injury [13]. Earlier studies implicated several aspects of SCD including volume depletion, rhabdomyolysis, infections and the use of non-steroidal analgesics (NSAIDs) as predisposing factors for AKI [13, 21, 22, 23, 24, 25]. A cascade of these events individually or in combination possibly generates a constellation of sterile inflammation and oxidative stress, which overwhelm the normal physiology and trigger several chronic and acute multiorgan damage including kidney injury in SCD. Recurrent episodes of IR injury trigger vasoocclusive pain crisis (VOC), one of the major causes for intensive care unit (ICU) admission for patients with SCD. This medically vulnerable population is at higher risk of developing AKI due to co-morbid conditions of kidney and other organs including heart and lung. Patients with SCD frequently develop cardiopulmonary events like pulmonary hypertension (PH) and acute chest syndrome (ACS) which often lead to premature death [26]. AKI is emerging as a major clinical concern among SCD patients hospitalized for VOC and acute chest syndrome (ACS). It has been reported in ~14% of adults [12] and 8% children [27] with ACS, and in 17% of children with VOC [28]. Additionally, while hyperfiltration and microalbuminuria are common in SCD [13], chronic kidney disease (CKD) occurs in up to 60% of these patients [17]. Recent epidemiological evidences increasingly indicate that CKD and AKI are linked and probably promote one another [29, 30]. Underlying CKD is now recognized as a clear risk factor for AKI, as both decreased glomerular filtration rate (GFR) and increased proteinuria.

2.1 Hemolysis and acute kidney injury in SCD

Acute exacerbation of anemia that potentially generate excess extracellular heme is an independent risk factor for AKI in SCD [27, 28, 31]. Earlier studies implicated several aspects of SCD including volume depletion, rhabdomyolysis, infections and the use of non-steroidal analgesics (NSAIDs) as predisposing factors for AKI [13, 21, 22, 23, 24, 25]. Recent clinical studies have concluded that incidences of AKI are associated with rapid decline in hemoglobin (Hb). The link between acute hemolysis and AKI is corroborated with significantly low level of total Hb at the time of hospitalization among SCD patients who develop AKI compared to those who do not [16], and higher risk of developing acute renal insufficiency among ACS patients with rapidly progressive decline in total Hb [32]. Intravascular hemolysis is a cardinal pathophysiological event in SCD that raises cell free plasma Hb and arginase-1 levels to collectively reduce nitric oxide (NO) bioavailability and enhance reactive oxygen species (ROS) formation [33, 34]. Cell-free hemoglobin is primarily scavenged by plasma protein haptoglobin (Hp). The resulting duo (Hb-Hp complex) is internalized by macrophage receptor CD163 for subsequent globin and heme metabolism. Haptoglobin is depleted in SCD resulting high amount of plasma hemoglobin that can easily get exposed to the underlying oxidative environment. Heme is subsequently released following oxidation of Hb to methemoglobin (metHb) with ferric heme. Extracellular circulating heme is rapidly transferred to hemopexin (Hx), the plasma protein with the highest binding affinity for heme. It is well known that heme-hemopexin (heme-Hx) complex is transported to the liver for degradation by heme oxygenase-1 (HO-1) [35, 36]. In SCD, plasma Hx is also intrinsically exhausted due to chronic hemolysis [37, 38]. Lack of haptoglobin and hemopexin along with chronic and acute hemolysis elevate extracellular hemoglobin and heme in plasma of SCD patients [33]. Furthermore, the HbS is a relatively unstable molecule that can easily undergo autooxidation contributing to increase circulating free heme in SCD [39]. Both cell-free circulating hemoglobin and heme are toxic, unless sufficiently metabolized, to the cells and may cause significant damage to organs including kidney.

2.2 Pathogenesis of acute kidney injury in SCD

The primary etiology of AKI involves four major structures of kidney including tubules, glomeruli, interstitium and intrarenal blood vessels. While acute tubular injury is the major pathological manifestation of AKI, rapid decline in renal function identified by reduced glomerular filtration rate (GFR) clinically define AKI [40]. The dimeric form of circulating cell free Hb can filter through glomerular sieve and enters in proximal tubular segment. The endocytosis of Hb molecules is possible through the megalin and cubilin receptors on tubular epithelial cells. The internalized hemoglobin breaks down in to heme that induces caspase-3 mediated apoptosis of the tubular cells leading to AKI development. This idea was supported by the presence of hemoglobin and myoglobin in plasma and urinary space in multiple in vivo models of AKI induced by glycerol, ischemia, sepsis and cisplatin [41, 42, 43].

In vivo, excess circulating heme, a byproduct of acute hemolysis, triggers VOC and ACS, the two major SCD complications associated with hospitalization and AKI development in SCD [44, 45]. Our recent study demonstrated that modest elevation of extracellular heme in circulation promotes clinically relevant AKI in an established humanized murine model of SCD containing human HbS. In this study, the researchers have established that a secondary heme scavenger, alpha-1-microglobin (A1M) is elevated in mice and human with SCD as an adaptive response to decreased hemopexin, the primary heme scavenger responsible for clearance of circulating free heme [46]. Several other studies have shown that heme bound to A1M is transported to renal tubular epithelial cells [47]. Excess deposition of heme causes proximal tubular epithelial cell death and promotes AKI (Figure 1). This study identifies that relative concentration of A1M and Hx may serve as prognostic factor of future AKI events in SCD during acute hemolytic events [46, 48].

Figure 1.

Pathogenesis of AKI in SCD. Hemolysis cause release of cell free Hb and heme in circulation. Free dimeric Hb or free heme bound to A1M passes through glomerular filtration and internalized into renal proximal tubular epithelial cells. Excess heme can overwhelm the HO-1 degradation capacity and induce multiple cell death pathways. On the other hand, Hb may cause podocyte injury leading to glomerular dysfunction. Tubular cell death and/or glomerular damage develops AKI.

Advertisement

3. Chronic kidney disease (CKD) in sickle cell disorders

Kidney diseases gradually develop in individuals with SCD. Microalbuminuria is evident in childhood, progressing to apparent proteinuria, deteriorating glomerular filtration rate (GFR) in early adulthood, while CKD becomes prevalent in adults [49]. Development of CKD in SCD is complex, but several studies have invariably demonstrated its association with low hemoglobin level and hemolysis [50, 51, 52, 53]. Higher frequency of severe anemia (Hb: 7–9 g/dl) among SCD patients with ESRD (71%) compared to non-SCD patients with ESRD (25%) has also been reported [54]. Moreover, among SCD patients, exacerbation of anemia is an independent risk factor for acute kidney injury (AKI) which is a predisposing factor for CKD and ESRD [27, 28, 31]. Progression of kidney damage is defined as CKD when eGFR is reduced to <60 mL/min/1.73 m2. The reduced GFR is often associated with hematuria, albuminuria and nephrotic syndromes. Intravascular hemolysis is a cardinal pathophysiological event in SCD that raises cell free plasma hemoglobin and arginase 1 to collectively reduce nitric oxide (NO) bioavailability and enhance reactive oxygen species (ROS) formation [33, 34]. Worsening anemia and elevated persistent oxidative stress lead to decline in GFR in association with reduced erythropoietin synthesis. Individuals with SCD develop CKD at a median age of 23.1 years, while 16–27% of pediatric patients have CKD [17].

3.1 Glomerular hyperfiltration, hyper perfusion and progressive kidney damage

Increased renal blood flow and higher GFR are characteristics of kidney function among SCD patients at their younger age. The hyperfiltration subsides to normal GFR that eventually lowers to subnormal level with the progression of age and the development of CKD [13, 55]. Sustained glomerular hyperfiltration causes damage to different parts of the glomerulus including the endothelium and the epithelial layer of the Bowman’s capsule. These events predispose the development of focal segmental glomerular sclerosis (FSGS), which is a common feature in SCD. Hyperfiltration occurs due to glomerular hyper perfusion that increases the renal blood flow. Hyper perfusion stems from underlying anemia and decreased vascular resistance, while the reduced blood flow is evident within hypoxic renal medulla due to vasoocclusion of sickle red blood cells. This phenomenon commonly known as “perfusion paradox” generates increased oxidative stress, mesangial proliferation, endothelial barrier disruption, and thickening of the glomerular basement membrane [56].

3.2 Proteinuria and chronic kidney disease in SCD

Hyperfiltration among children with SCD is associated with proteinuria in the form of microalbuminuria (urine albumin 30–300 mg/g creatinine). This condition increases with age and about 68% of these patients experienced macroalbuminuria (urine albumin >300 mg/g creatinine) as they grow older [57, 58]. While about 4% of SCD patients exhibit macroalbuminuria at the nephrotic range (urine albumin >500 mg/g creatinine), a substantial number of patients suffer from irreversible kidney complications. Several studies have indicated association of albuminuria with hemolysis, incidences of vasoocclusive crisis and acute chest syndrome, and pulmonary hypertension. These events also impact blood pressure which in turn can regulate hyperfiltration [13, 17, 21, 53].

3.3 Genetic variants associated with chronic kidney disease in SCD

Apart from the underlying hemoglobin gene mutation, progression and severity of CKD development are associated with polymorphisms of multiples genes among SCD patients. A major proportion of SCD population has alpha thalassemia. Two polymorphisms in the α-chain of the globin chain including i) a 3.7 Kb deletion and ii) a 4.2 Kb deletion are associated with reduced albuminuria, higher eGFR and hence lower risk of CKD progression [59, 60].

The variants of apolipoprotein L1 gene (APOL1)gene associated with risk of CKD development have been studied widely. The G1 (S342G and I384M) as well as G2 (N388 and Y389 deletion) variants found in 11–13% of African Americans account for about 70% CKD risk in this population. Homozygous or compound heterozygous inheritance of G1/G2 variants within SCD population increase the macroalbuminuria, progression of CKD and development of ESRD [61, 62, 63].

Besides the increased risk of AKI with longer GT tandem repeats of HMOX-1 gene promoter, the allele frequency of a variant of HMOX-1(rs743811) was found to be associated with worsening CKD [61, 64]. Several other genetic variants including (i) Duffy antigen (Fy rs2814778) of the RBC, (ii) myosin heavy chain 9 (MYH9-rs5750248, rs1192763), (iii) TGF-β/BMP(BMPR1B) have also been implicated with CKD risk among various cohorts of SCD patients [65, 66, 67].

3.4 Renal endothelium and pathogenesis of chronic kidney disease in SCD

In SCD, intrinsic hemolytic, inflammatory, oxidative and hypercoagulative stress contribute to the characteristic endothelial dysfunction that alters the systemic vascular biology [68]. Endothelial interaction with multiple blood components, including sickled red blood cells, leukocytes and platelets, injure the endothelium and obstruct the vasculature impacting internal organs [69]. Renal pathology in sickle cell nephropathy includes extensive peritubular microvascular congestions and chronic thrombotic microangiopathy that can lead to CKD by peritubular microvascular rarefaction, interstitial fibrosis and tubular atrophy [70, 71, 72].

Several studies including ours have demonstrated that extracellular heme triggers endothelial barrier disruption in various organs in SCD including the kidneys [44, 73, 74, 75, 76]. Endothelial dysfunction may occur in the glomerulus affecting the podocytes that maintain the glomerular endothelial integrity. One study has shown that renal endothelial dysfunction is triggered by an increase in soluble fms-like tyrosine kinase 1 (sFLT-1), a splice variant of vascular endothelial growth factor receptor-1 (VEGFR1) in SCD. The sFLT-1 blocks interaction of VEGF with glomerular endothelium leading to endothelial damage associated with increased albuminuria [77]. Moreover, endothelin-1 (ET-1) generated by endothelial cells under inflammation causes endothelial injury by reducing NO bioavailability. Alongside, ET-1 mediates podocyte injury by binding endothelin A (ETA) receptor. In animal studies, antagonists to ETA receptor showed renal protection [78, 79].

Hemolysis and hemoglobinuria, cardinal features of SCD are associated with proteinuria and progression of CKD in SCD patients [51, 53]. Multiple chronic and acute hemolytic events may induce episodes of vasoocclusion leading to vulnerability of the endothelium susceptible to injury. The peritubular capillaries may split leading hematuria through extravasation of RBCs. These events may prompt development of vasoocclusion of vasa recta and papillary necrosis [80].

Endothelial injury in the renal peritubular microvessels is closely linked to rarefaction and interstitial fibrosis that leads to CKD progression [81, 82, 83]. Moreover, free heme reflects the function of danger associated molecular pattern in hemolytic diseases activating vital defense response compartments including toll-like receptor-4 signaling, neutrophil extracellular trap formation and inflammasome activation [84, 85, 86]. The inflammatory milieu including activated neutrophils regulate endothelial barrier function through adhesion and secretion dependent mechanisms [87].

Advertisement

4. Current management and therapies

Medications and timely management are critical in protecting the kidney. Chronic RBC transfusion therapy is offered to enhance the osmolality and concentrating ability in children with SCD. Hydroxyurea therapy has been shown to reduce the hyperfiltration in children [88]. Hypotonic fluid is recommended for renal papillary necrosis thiazide or loop diuretics are used to maintain urine flow rate [80]. The angiotensin converting enzyme inhibitors (ACE-inhibitors) can dilate efferent arterioles and help decrease glomerular pressure. ACE-inhibitors are used widely to control albuminuria [89].

Advertisement

5. Future research perspectives

Free heme is considered as an eDAMP (erythroid danger-associated molecular pattern) that induces sterile inflammation in SCD. Heme has been shown to activate toll-like receptor 4 (TLR4) on endothelial cell surface to promote TNFα stimulating innate immune signaling in SCD [45]. Moreover, heme activates NLRP3 inflammasome pathway and releases caspase-1 induced IL-1β from macrophages. The resulting inflammation is associated with hemolysis induced lethality in SCD mice and heme induced cell death in macrophages [85]. Heme-mediated toxicity is particularly relevant to renal tubular epithelial cells as these cells presumably confront the majority of heme that passes through the glomeruli during acute hemolysis. Inflammasomes potentially activate caspase-1 that mediates cell death leading to release of IL-1β and IL-18. These are pro-inflammatory cytokines that are induced and cleaved in the proximal tubule, and subsequently easily detected in the urine of SCD patients and their concentrations were associated with hemolysis [90]. In a cross-sectional study, urine IL-18 levels were markedly elevated in patients with established AKI [91]. An in vitro study using immortalized human proximal tubular epithelial cells (HK-2) suggests that activation of inflammasomes mediates contrast-induced AKI [92]. Whether acute hemolytic events followed by exposure of excess heme on proximal tubular epithelial cell surface induces AKI facilitated by stimulation of inflammasome machinery has not yet been established.

The role of the rate limiting heme catabolizing enzyme, HO-1 may be of significant importance. HO-1 degrades heme into iron (Fe), carbon monoxide (CO) and biliverdin, and thereby protects against adverse effects of heme. Multiple studies featured rapid induction of HO-1 under oxidative stress accounts for its beneficial effect against kidney injury [93, 94, 95]. Moreover, longer [GT]n repeats in HO-1 gene (HMOX1) promoter, responsible for reduced HO-1 expression, is associated with increased risk of AKI in sickle cell disease patients [16]. The mechanism of cellular regulation of HO-1 induction during AKI events in SCD has yet to be elucidated.

Besides tubular damage, etiology of AKI also includes impaired glomerular structure. Podocytes, the highly differentiated visceral epithelial cells, is a major constituent of glomerular structure and function. One in vitro study has shown that human and murine podocytes exposed to Hb develops increased oxidative stress and undergo apoptosis resulting podocyte dysfunction [96]. In SCD, the cell free HbS may serve as an oxidant to cause podocyte injury that may contributes to AKI, whereas, multiple AKI events may induce focal segmental glomerulosclerosis (FSGS), a characteristic CKD feature in SCD.

The intracellular signaling within the podocyte regulating glomerular endothelial integrity has not been explained.

Despite clinical association, mechanistic studies linking hemolysis to renal peritubular endothelial impairment leading to progressive kidney diseases in SCD have not yet been described. The underlying chronic inflammation in SCD leads to activation of blood cells including neutrophils and platelets. During AKI and CKD, neutrophil and platelet accumulation are evident within renal vasculature. The cellular and molecular mechanism depicting the interactions of activated blood cells and the endothelium leading to progression of CKD is an important area of future research.

Kidney injuries in SCD is multifactorial and may involve multiple unique and overlapping cell biological events in several renal compartments (Figure 2). Incidences of AKI are generally considered as independent risk factor for CKD progression not only in general population but also in SCD. Multiple AKI events attributed to acute intravascular hemolytic events in SCD may be responsible for progressive CKD and end stage renal disease among SCD patients. Future studies elucidating mechanisms of AKI to CKD transition along with identification of specific risk factors are warranted for development of potential therapeutics to protect individuals with SCD from broad spectrum of renal complications.

Figure 2.

Overview of sickle cell disease nephropathy. Figure prepared with biorender.com.

Advertisement

Acknowledgments

Samit Ghosh is supported in part by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [grant R01DK124426]. The author acknowledges research support from Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania and Vitalant.

References

  1. 1. Ballas SK. The cost of health care for patients with sickle cell disease. American Journal of Hematology. 2009;84(6):320-322
  2. 2. Yeruva SL et al. Renal failure in sickle cell disease: Prevalence, predictors of disease, mortality and effect on length of hospital stay. Hemoglobin. 2016;40(5):295-299
  3. 3. Weatherall DJ. Genomics and global health: Time for a reappraisal. Science. 2003;302(5645):597-599
  4. 4. Weatherall DJ. Hemoglobinopathies worldwide: Present and future. Current Molecular Medicine. 2008;8(7):592-599
  5. 5. Piel FB et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151
  6. 6. Piel FB et al. Global burden of sickle cell anaemia in children under five, 2010-2050: Modelling based on demographics, excess mortality, and interventions. PLoS Medicine. 2013;10(7):e1001484
  7. 7. Kauf TL et al. The cost of health care for children and adults with sickle cell disease. American Journal of Hematology. 2009;84(6):323-327
  8. 8. Chawla LS et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. The New England Journal of Medicine. 2014;371(1):58-66
  9. 9. Leung KC, Tonelli M, James MT. Chronic kidney disease following acute kidney injury-risk and outcomes. Nature Reviews: Nephrology. 2013;9(2):77-85
  10. 10. Venkatachalam MA et al. Acute kidney injury: A springboard for progression in chronic kidney disease. American Journal of Physiology: Renal Physiology. 2010;298(5):F1078-F1094
  11. 11. Sklar AH et al. Acute renal failure in sickle cell anemia. The International Journal of Artificial Organs. 1990;13(6):347-351
  12. 12. Audard V et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrology, Dialysis, Transplantation. 2010;25(8):2524-2529
  13. 13. Nath KA, Hebbel RP. Sickle cell disease: Renal manifestations and mechanisms. Nature Reviews: Nephrology. 2015;11(3):161-171
  14. 14. Cecchini J et al. Outcomes of adult patients with sickle cell disease admitted to the ICU: A case series*. Critical Care Medicine. 2014;42(7):1629-1639
  15. 15. McCormick M et al. Acute kidney injury in paediatric patients with sickle cell disease is associated with increased morbidity and resource utilization. British Journal of Haematology. 2020;189(3):559-565
  16. 16. Saraf SL et al. HMOX1 and acute kidney injury in sickle cell anemia. Blood. 2018;132(15):1621-1625
  17. 17. Powars DR et al. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Annals of Internal Medicine. 1991;115(8):614-620
  18. 18. Bunn HF. Pathogenesis and treatment of sickle cell disease. The New England Journal of Medicine. 1997;337(11):762-769
  19. 19. Pauling L and ITANO HA. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-548
  20. 20. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of Clinical Investigation. 2017;127(3):750-760
  21. 21. Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. American Journal of Hematology. 2000;63(4):205-211
  22. 22. Allon M. Renal abnormalities in sickle cell disease. Archives of Internal Medicine. 1990;150(3):501-504
  23. 23. de Jong PE, van Statius Eps LW. Sickle cell nephropathy: New insights into its pathophysiology. Kidney International. 1985;27(5):711-717
  24. 24. Alleyne GA. The kidney in sickle cell anemia. Kidney International. 1975;7(6):371-379
  25. 25. Buckalew VM Jr, Someren A. Renal manifestations of sickle cell disease. Archives of Internal Medicine. 1974;133(4):660-669
  26. 26. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annual Review of Pathology. 2019;14:263-292
  27. 27. Lebensburger JD et al. Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome. Pediatric Nephrology. 2016;31(8):1363-1368
  28. 28. Baddam S et al. Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis. Pediatric Nephrology. 2017;32(8):1451-1456
  29. 29. Hsu CY. Yes, AKI truly leads to CKD. Journal of American Society Nephrology. 2012;23(6):967-969
  30. 30. Hsu RK, Hsu CY. The role of acute kidney injury in chronic kidney disease. Seminars in Nephrology. 2016;36(4):283-292
  31. 31. Aban I et al. Severe anemia early in life as a risk factor for sickle-cell kidney disease. Blood. 2017;129(3):385-387
  32. 32. Chaturvedi S et al. Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: A distinct acute chest syndrome phenotype. American Journal of Hematology. 2016;91(12):1185-1190
  33. 33. Reiter CD et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature Medicine. 2002;8(12):1383-1389
  34. 34. Gladwin MT, Kanias T, Kim-Shapiro DB. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. The Journal of Clinical Investigation. 2012;122(4):1205-1208
  35. 35. Docherty JC et al. Mechanism of action of heme oxygenase. A study of heme degradation to bile pigment by 18O labeling. The Journal of Biological Chemistry. 1984;259(21):13066-13069
  36. 36. Belcher JD et al. Heme degradation and vascular injury. Antioxidants & Redox Signaling. 2010;12(2):233-248
  37. 37. Muller-Eberhard U et al. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood. 1968;32(5):811-815
  38. 38. Wochner RD et al. Hemopexin metabolism in sickle-cell disease, porphyrias and control subjects-effects of heme injection. The New England Journal of Medicine. 1974;290(15):822-826
  39. 39. Hebbel RP et al. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(1):237-241
  40. 40. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Comprehensive Physiology. 2012;2(2):1303-1353
  41. 41. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: Implications for kidney disease. Journal of American Society Nephrology. 2007;18(2):414-420
  42. 42. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney International. 1996;49(2):314-326
  43. 43. Gliozzi ML et al. Hemoglobin alters vitamin carrier uptake and vitamin D metabolism in proximal tubule cells: Implications for sickle cell disease. American Journal of Physiology: Cell Physiology. 2019;317(5):C993-C1000
  44. 44. Ghosh S et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. The Journal of Clinical Investigation. 2013;123(11):4809-4820
  45. 45. Belcher JD et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390
  46. 46. Ofori-Acquah SF et al. Hemopexin deficiency promotes acute kidney injury in sickle cell disease. Blood. 2020;135(13):1044-1048
  47. 47. Larsson J, Allhorn M, Kerstrom B. The lipocalin alpha(1)-microglobulin binds heme in different species. Archives of Biochemistry and Biophysics. 2004;432(2):196-204
  48. 48. Saraf SL. Heme A1M’ed at the kidney in sickle cell disease. Blood. 2020;135(13):979-981
  49. 49. Gosmanova EO et al. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. Journal of Investigative Medicine. 2014;62(5):804-807
  50. 50. Lebensburger J et al. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. American Journal of Hematology. 2011;86(5):430-432
  51. 51. Day TG et al. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica. 2012;97(2):201-205
  52. 52. Gurkan S et al. Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia. Pediatric Nephrology. 2010;25(10):2123-2127
  53. 53. Hamideh D et al. Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. Pediatric Nephrology. 2014;29(10):1997-2003
  54. 54. McClellan AC et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. British Journal of Haematology. 2012;159(3):360-367
  55. 55. Praga M et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. American Journal of Kidney Diseases. 1999;33(1):52-58
  56. 56. Helal I et al. Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nature Reviews: Nephrology. 2012;8(5):293-300
  57. 57. Vazquez B et al. Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia. American Journal of Hematology. 2014;89(12):1156-1157
  58. 58. Guasch A et al. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure. Journal of American Society Nephrology. 2006;17(8):2228-2235
  59. 59. Guasch A et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. Journal of American Society Nephrology. 1999;10(5):1014-1019
  60. 60. Nebor D et al. Alpha-thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients. Blood Cells, Molecules & Diseases. 2010;45(2):154-158
  61. 61. Saraf SL et al. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica. 2015;100(10):1275-1284
  62. 62. Ashley-Koch AE et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. British Journal of Haematology. 2011;155(3):386-394
  63. 63. Kormann R et al. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: Kidney is the main target. British Journal of Haematology. 2017;179(2):323-335
  64. 64. Geard A et al. Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. British Journal of Haematology. 2017;178(4):629-639
  65. 65. Afenyi-Annan A et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion. 2008;48(5):917-924
  66. 66. Nolan VG et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. American Journal of Hematology. 2007;82(3):179-184
  67. 67. Kopp JB et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature Genetics. 2008;40(10):1175-1184
  68. 68. Kato GJ et al. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology. 2009;84(9):618-625
  69. 69. Zhang D et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127(7):801-809
  70. 70. Bissonnette ML et al. Medullary microvascular thrombosis and injury in sickle hemoglobin C disease. Journal of American Society Nephrology. 2016;27(5):1300-1304
  71. 71. Lusco MA et al. AJKD atlas of renal pathology: Sickle cell nephropathy. American Journal of Kidney Diseases. 2016;68(1):e1-e3
  72. 72. Kida Y, Tchao BN, Yamaguchi I. Peritubular capillary rarefaction: A new therapeutic target in chronic kidney disease. Pediatric Nephrology. 2014;29(3):333-342
  73. 73. Ghosh S, Tan F, Ofori-Acquah SF. Spatiotemporal dysfunction of the vascular permeability barrier in transgenic mice with sickle cell disease. Anemia. 2012;2012:582018
  74. 74. Wagener FA et al. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood. 2001;98(6):1802-1811
  75. 75. Qiu Y et al. Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease. Nature Biomedical Engineering. 2018;2:453-463
  76. 76. Singla S et al. Hemin causes lung microvascular endothelial barrier dysfunction by necroptotic cell death. American Journal of Respiratory Cell and Molecular Biology. 2017;57(3):307-314
  77. 77. Ataga KI et al. Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: Potential role of soluble fms-like tyrosine kinase-1. European Journal of Haematology. 2010;85(3):257-263
  78. 78. Heimlich JB et al. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species. British Journal of Pharmacology. 2016;173(2):386-395
  79. 79. Kasztan M et al. Long-term Endothelin-A receptor antagonism provides robust renal protection in humanized sickle cell disease mice. Journal of American Society Nephrology. 2017;28(8):2443-2458
  80. 80. Scheinman JI. Sickle cell disease and the kidney. Nature Clinical Practice: Nephrology. 2009;5(2):78-88
  81. 81. Ehling J et al. Quantitative micro-computed tomography imaging of vascular dysfunction in progressive kidney diseases. Journal of American Society Nephrology. 2016;27(2):520-532
  82. 82. Bábíčková J et al. Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular capillaries. Kidney International. 2017;91(1):70-85
  83. 83. Lindenmeyer MT et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. Journal of American Society Nephrology. 2007;18(6):1765-1776
  84. 84. Graça-Souza AV et al. Neutrophil activation by heme: Implications for inflammatory processes. Blood. 2002;99(11):4160-4165
  85. 85. Dutra FF et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(39):E4110-E4118
  86. 86. Chen G et al. Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood. 2014;123(24):3818-3827
  87. 87. Ma Y et al. Role of neutrophil extracellular traps and vesicles in regulating vascular endothelial permeability. Frontiers in Immunology. 2019;10:1037
  88. 88. Alvarez O et al. Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood & Cancer. 2012;59(4):668-674
  89. 89. Quinn CT et al. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. American Journal of Hematology. 2017;92(9):E520-E528
  90. 90. Cerqueira BA et al. Increased concentrations of IL-18 and uric acid in sickle cell anemia: Contribution of hemolysis, endothelial activation and the inflammasome. Cytokine. 2011;56(2):471-476
  91. 91. Parikh CR et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. Journal of American Society Nephrology. 2005;16(10):3046-3052
  92. 92. Shen J et al. NLRP3 inflammasome mediates contrast media-induced acute kidney injury by regulating cell apoptosis. Scientific Reports. 2016;6:34682
  93. 93. Nath KA et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. The Journal of Clinical Investigation. 1992;90(1):267-270
  94. 94. Lever JM et al. Heme Oxygenase-1 in kidney health and disease. Antioxidants & Redox Signaling. 2016;25(3):165-183
  95. 95. Ramos S et al. Renal control of disease tolerance to malaria. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(12):5681-5686
  96. 96. Rubio-Navarro A et al. Podocytes are new cellular targets of haemoglobin-mediated renal damage. The Journal of Pathology. 2018;244(3):296-310

Written By

Samit Ghosh

Submitted: January 10th, 2022 Reviewed: January 24th, 2022 Published: February 23rd, 2022